

Urgent Field Safety Notice Radial Fiber TXMF600R

For Attention of*: purchasing department or person responsible for quality and regulatory requirements

Contact details

Tobrix BV

Van Dijklaan 27 5581 WG Waalre The Netherlands

Tel: +31 40 223 0773 Email: koen@tobrix.com

Dear Customer,

We, Tobrix BV, are conducting a field safety corrective action concerning LOT **2111049** of the 600mu radial fiber **TXMF600R**.

Please read this letter carefully and take the appropriate action as outlined in part 3

Tobrix

FSN reference nr.: 202203

Date: 25-11-2022

Urgent Field Safety Notice (FSN) Radial Fiber Risk addressed by FSN

	1. Information on Affected Devices*		
1	1. Device Type(s)*		
•	Sterile surgical laser fiber 'radial fiber' 600mu for EVLA treatments		
1	2. Commercial name(s)		
	Radial fiber		
1	Unique Device Identifier(s) (UDI-DI)		
	n/a		
1	4. Primary clinical purpose of device(s)*		
	Endovenous laser ablation		
1	5. Device Model/Catalogue/part number(s)*		
	TXMF600R		
1	6. Software version		
	n/a		
1	7. Affected serial or lot number range		
	LOT: 2111049		
1	Associated devices		
	n/a		

	2 Reason for Field Safety Corrective Action (FSCA)*			
2	Description of the product problem*			
	Tip breaks of with little force			
2	2. Hazard giving rise to the FSCA*			
	The broken tip can remain in the patient. If this occurs close to the crosse it may present a hazard, requiring surgical removal of the tip			
2	3. Probability of problem arising			
	2 out of 50 known incidences, so 4%			
2	4. Predicted risk to patient/users			
	Severity is low, probability is 4% so risk is low			
2	Further information to help characterise the problem			
2	6. Background on Issue			
	Incident was reported by healthcare facility after 2 incidences. In both cases the tip			
	broke off shortly after starting lasering.			
2	7. Other information relevant to FSCA			
	This field may only contain additional information that is deemed necessary by the manufacturer			
	to supplement information relevant to the FSCA.			



FSN reference nr.: 202203

Date: 25-11-2022

		3. Type of Action to mitigate the risk*				
3.	1.	Action To Be Taken by the User*				
			antine Device ⊠ Return	Device ☐ Destroy Device		
		☐ On-site device modification/inspection				
		☐ Follow patient management recommendations				
		\square Take note of amendment/reinforcement of Instructions For Use (IFU)				
		□ Other □ None				
		Devices can be returned to our office at: Van Dijklaan 27 5581WG Waalre The Netherlands				
3.	2.	By when should the action be completed?	Identify and quarantir within one week if po	ne device ASAP. Return device ssible		
3.	3.	Particular considerations for	Choose an item.			
		Is follow-up of patients or review of patients' previous results recommended? Choose an item. Provide further details of patient-level follow-up if required or a justification why none is				
3.	4.	required 4. Is customer Reply Required? * Yes		Yes		
		If yes, form attached specifying deadline for return) Please respond before 02-12-2022				
3.	5.	Action Being Taken by	the Manufacturer			
		☐ Software upgrade ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	☐ On-site device modification/inspace ☐ IFU or labelling change ☐ None	pection		
		LOT will be removed and investig				
3		By when should the action be completed?	Specify where critical to pat	tient/end user safety		
3.	7.	Is the FSN required to be communicated to the patient No /lay user?				
3	8.	If yes, has manufacturer provided additional information suitable for the patient/lay				
		user in a patient/lay or non-professional user information letter/sheet? Choose an item. Choose an item.				

FSN reference	nr.: 202203

Date: 25-11-2022

	4. General Information*			
4.	1. FSN Type*	New		
4.	For updated FSN, reference number and date of previous FSN	Provide reference and date of previous FSN if relevant		
4. 3. For Updated FSN, key new information as follows:				
	Summarise any key difference in devi	ces affected and/or action to be taken.		
4.	4. Further advice or information already expected in follow-up FSN? *	No		
5. If follow-up FSN expected, what is the further advice expected Eg patient management, device modifications etc		the further advice expected to relate to:		
		ications etc		
4	Anticipated timescale for follow- up FSN	For provision of updated advice.		
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)			
	a. Company Name	Only necessary if not evident on letter-head.		
	b. Address	Only necessary if not evident on letter-head.		
	c. Website address	Only necessary if not evident on letter-head.		
4.	The Competent (Regulatory) Authority of your country has been informed about this communication to customers.			
4.	9. List of attachments/appendices:	If extensive consider providing web-link instead.		
4.	10. Name/Signature	Koen Stokbroekx, PRRC		
		tollar		

Transmission of this Field Safety Notice

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.